Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843235 | 1.00 | CA1 (0.59) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL13764949 | 1.00 | CA1 (0.59) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL14314683 | 0.92 | CA1 (0.55) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL14135218 | 0.91 | CA1 (0.54) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL26986088 | 0.84 | CA1 (0.61) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL19660910 | 0.83 | CA1 (0.49) | CA1CA2IDO1AGXTSLC6A4 | |
| SCHEMBL14538696 | 0.83 | CA1 (0.73) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL1194330 | 0.83 | CA1 (0.73) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL1194332 | 0.83 | CA1 (0.73) | CA1CA2IDO1AGXTCYP2C9 | |
| SCHEMBL29127933 | 0.83 | CA1 (0.55) | CA1CA2IDO1AGXTSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7700783-B2 | Synthesis of discodermolide and variants thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-04-20 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| EP-1521752-B1 | MACROCYCLES FOR THE TREATMENT OF CANCER | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20070276144-A1 | Synthesis Of Discodermolide And Variants Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2007-11-29 | — | — | US | disclosed |
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | WOLFGANG RICHTER (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1521752-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | Gesellschaft fur Biotechnologische Forschung mbH (gbf) (DE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007492-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | GESELLSCHAFT FUER BIOTECHNOLGISCHE FORSCHUNG MBH (GBF) (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | TTPA, THPO, TERT | CA1 4725/4885CA2 4710/4885IDO1 2992/4885 |
| US-20070276144-A1 | Synthesis Of Discodermolide And Variants Thereof | EML4, CYP17A1, CYP21A2 | CA1 4222/4885CA2 4683/4885IDO1 4182/4885 |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | CCNI, CCNB1, CCNC | CA1 3681/4885CA2 3910/4885IDO1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.